Cognition Therapeutics Presenting New Analyses from Ongoing Clinical Trial of CT1812 in Mild-to-Moderate Alzheimer’s Disease

Rhea-AI Summary

Cognition Therapeutics (NASDAQ: CGTX) announces its participation in the 2022 Alzheimer’s Association International Conference (AAIC) from July 31 to August 4. The company will present new proteomic analyses from the SPARC clinical study, showcasing the impact of CT1812 on Alzheimer’s disease biomarkers. CT1812, an oral small molecule targeting sigma-2 receptors, shows potential therapeutic benefits. Cognition is conducting multiple clinical studies, with results from SHINE and SEQUEL expected in early 2023. The company has secured over $168 million in grant funding.

Positive

• CT1812 shows potential therapeutic benefits for Alzheimer's and dementia.
• Successful dosing of the first participant in the Phase 2 SHIMMER clinical study.
• Expected top-line results from SHINE and SEQUEL studies in early 2023.
• Ongoing collaboration with the Alzheimer’s Clinical Trials Consortium.
• Over $168 million in grant funding secured from the National Institute of Aging.

Negative

• None.

 - Analyses Demonstrate CT1812 Impact on Alzheimer’s Disease Processes -

NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) will be in attendance at the 2022 Alzheimer’s Association International Conference (AAIC) being held in San Diego, CA from July 31 to August 4, 2022. Cognition’s vice president of research, Mary Hamby, Ph.D. will present new proteomic analyses of disease biomarkers demonstrating the impact of CT1812 on disease processes in participants from the SPARC clinical study in mild-to-moderate Alzheimer’s disease.

CT1812 is an oral, small molecule that selectively binds to the sigma-2 (σ-2) receptor complex. Evidence implicates σ-2 receptors in the regulation of key cellular processes that are damaged in Alzheimer’s disease, dementia with Lewy bodies (DLB) and other neurodegenerative disorders.

“Our approach to protecting neurons by targeting the σ-2 receptor complex is unique in a field that has been long focused on lowering amyloid plaque,” stated Lisa Ricciardi, president and CEO of Cognition Therapeutics. “The company is encouraged by results to date from our development programs and believes this approach may have therapeutic potential in Alzheimer’s disease as well as DLB, an aggressive form of dementia with no approved treatments.”

For the first time at AAIC, Cognition is hosting a scientific exhibit booth where clinicians and researchers can learn more about the company’s clinical research initiatives.

Cognition’s ongoing clinical studies:

• DLB: the company recently announced that it dosed the first individual in its Phase 2 SHIMMER clinical study
• Mild-to-moderate Alzheimer’s disease: SHINE and SEQUEL are expected to yield top-line results in early 2023
• Early Alzheimer’s disease: In partnership with the Alzheimer’s Clinical Trials Consortium (ACTC), the START study (n=540) is expected to commence dosing by end of year
  

Cognition’s clinical programs, including the above four studies, are supported by grant funding exceeding $168 million awarded by the National Institute of Aging.

AAIC Exhibit details (July 31-August 3):  
Cognition Booth: #105 (Hall E)
Cognition Business Suite: E15 (Hall D)

AAIC Presentation details (August 4 at 10:45 a.m. PT):  

	Title:	CSF proteomics analysis to investigate the pharmacodynamic response of the S2R modulator CT1812 in Alzheimer’s disease patients from the SPARC clinical trial
	Authors:	Pandey K, Waybright L, Duong DM, Malagise E, Blennow K, Zetterberg H, Mecca AP, van Dyck C, Caggiano AO, Seyfried NT, Hamby ME

About Cognition Therapeutics, Inc. 
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com/. 

Forward Looking Statements  
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and are available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events or results. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. 

Contact Information: 
Cognition Therapeutics, Inc. 
info@cogrx.com 

Aline Sherwood (media) 
Scienta Communications 
asherwood@scientapr.com  

Daniel Kontoh-Boateng (investors) 
Tiberend Strategic Advisors, Inc. 
dboateng@tiberend.com 

FAQ

What is CT1812 and its significance in Alzheimer's treatment?

CT1812 is an oral small molecule that targets sigma-2 receptors, showing potential to affect Alzheimer's disease processes.

What are the upcoming results for Cognition Therapeutics' studies?

Top-line results from the SHINE and SEQUEL studies are expected in early 2023.

When is Cognition Therapeutics presenting at the AAIC?

Cognition will present on August 4 at 10:45 a.m. PT.

What types of studies is Cognition Therapeutics conducting?

Cognition is conducting studies on Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration.

How much funding has Cognition Therapeutics received for its clinical programs?

Cognition has secured over $168 million in grant funding from the National Institute of Aging.